Health Affairs, 25, no. 3 (2006): 635-646
doi: 10.1377/hlthaff.25.3.635
© 2006 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Huskamp, H. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Huskamp, H. A.
Related Collections
* Managed Care - Mental Health
* Business Of Health
* Mental Health/Substance Abuse
* Pharmaceuticals
* Research And Technology
* Health Spending
* Consumer Issues

Finance & Value

Prices, Profits, And Innovation: Examining Criticisms Of New Psychotropic Drugs’ Value

Haiden A. Huskamp

High profits and high drug costs have brought increased scrutiny of the pharmaceutical industry over the issue of whether the drugs they produce are worth the costs. I examine several related complaints, including the proliferation of me-too drugs and product reformulations, which some argue have little value relative to their cost; the baseless promotion of newer drug classes as more effective than existing, less expensive drugs; legal strategies to extend market exclusivity that result in high brand-name drug prices for an extended period of time; and large promotional expenditures that result in higher prices.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
M. E. Domino and M. S. Swartz
Who Are the New Users of Antipsychotic Medications?
Psychiatr Serv, May 1, 2008; 59(5): 507 - 514.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
R. A. Rosenheck, D. L. Leslie, and J. A. Doshi
Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Psychiatr Serv, May 1, 2008; 59(5): 515 - 520.
[Abstract] [Full Text] [PDF]